Safety and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% in the Treatment of Bacterial Conjunctivitis: Data from Six Clinical and Phase I Safety Studies

Author： Comstock Timothy L.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.30, Iss.10, 2010-10, pp. : 675-685

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% in Children and Adolescents with Bacterial Conjunctivitis: A Post Hoc, Subgroup Analysis of Three Randomized, Double-Masked, Parallel-Group, Multicenter Clinical Trials

By Comstock Timothy L.  

Pediatric Drugs, Vol. 12, Iss. 2, 2010-04 ,pp. : 105-112

Adis International

Access to resources Recommend Favorite

Besifloxacin Ophthalmic Suspension 0.6% Administered Twice Daily for 3 Days in the Treatment of Bacterial Conjunctivitis in Adults and Children

By DeLeon Jesse  

Clinical Drug Investigation, Vol. 32, Iss. 5, 2012-05 ,pp. : 303-317

Adis International

Access to resources Recommend Favorite

Besifloxacin Ophthalmic Suspension 0.6%

By Carter Natalie J.   Scott Lesley J.  

Drugs, Vol. 70, Iss. 1, 2010-01 ,pp. : 83-97

Adis International

Access to resources Recommend Favorite

Memantine for the Treatment of Alzheimer's Disease: Tolerability and Safety Data from Clinical Trials

By Farlow Martin R.  

Drug Safety, Vol. 31, Iss. 7, 2008-01 ,pp. : 577-585

Adis International

Access to resources Recommend Favorite

Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial

By Anghelescu I.   Szegedi A.   Schlegel S.   Weigmann H.   Hiemke C.   Wetzel H.  

European Neuropsychopharmacology, Vol. 8, Iss. 4, 1998-12 ,pp. : 315-320

Elsevier

Access to resources Recommend Favorite